Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway
Authors:
Open Access
- 18 March 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 173, 116445
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Anhui Province (2008085MH261)
- Natural Science Foundation of Anhui Province (2208085QH282)
- Anhui Provincial Department of Education (JK2019A1107)
- Anhui Provincial Department of Education (2022AH052333)
This publication has 47 references indexed in Scilit:
- Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phaseInvestigational New Drugs, 2023
- A novel mechanism of cannabidiol in suppressing ovarian cancer through LAIR ‐1 mediated mitochondrial dysfunction and apoptosisEnvironmental Toxicology, 2023
- New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung CancerCurrent Treatment Options in Oncology, 2022
- Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis ComplexJAMA Neurology, 2021
- Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemiaCancer, 2019
- The Use of Medical Marijuana in CancerCurrent Oncology Reports, 2016
- Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancerApoptosis, 2014
- Dasatinib combined with docetaxel for castration‐resistant prostate cancerCancer, 2011
- Local regulation of human breast xenograft modelsJournal of Cellular Physiology, 2010
- The Effect of the Cyclin-Dependent Kinase Inhibitor Olomoucine on Cell Cycle KineticsExperimental Cell Research, 1997